NEOGENOMICS INC — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-03-02

Reporting Person: CARDOZA GEORGE (President, Pharma Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-02	Common Stock	A	6207	—	Acquired	377109	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-02	Stock Option (Right to Buy)	$53.17	A	35171	Acquired	2028-03-02	Common Stock (35171.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (50000.0)	50000	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (192500.0)	192500	Direct
Stock Option (Right to Buy)	$19.6	2024-03-01	Common Stock (51459.0)	51459	Direct
Stock Option (Right to Buy)	$28.33	2027-03-02	Common Stock (48768.0)	48768	Direct

Footnotes

F1: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F2: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F3: On March 1, 2019, Mr. Cardoza was granted 51,459 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F4: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.